Copyright
©The Author(s) 2015.
World J Gastroenterol. Apr 21, 2015; 21(15): 4696-4706
Published online Apr 21, 2015. doi: 10.3748/wjg.v21.i15.4696
Published online Apr 21, 2015. doi: 10.3748/wjg.v21.i15.4696
Table 1 Baseline demographic characteristics, classified by treatment
Baseline characteristics | Triple therapy (n = 88) | Dual therapy (n = 122) | P value |
Age, yr | 63 (53-68) | 60 (52-65) | 0.101 |
Male | 37 (42.1) | 52 (42.6) | 0.933 |
Body weight, kg | 56 (49-67) | 58 (50-66) | 0.782 |
Body mass index, kg/m2 | 22.7 (20.7-25.1) | 22.8 (20.6-24.9) | 0.859 |
Serum AFP level, ng/mL | 4.5 (2.8-9.0) | 4.0 (2.8-8.9) | 0.677 |
Serum AFP level < 5 ng/mL | 50 (56.8) | 70 (57.4) | 0.967 |
Serum AFP level 5-9.9 ng/mL | 18 (20.5) | 26 (21.3) | |
Serum AFP level ≥ 10 ng/mL | 20 (20.7) | 26 (21.3) | |
HCV RNA level, log10 IU/mL | 6.5 (6.1-6.9) | 6.3 (5.8-6.6) | 0.010 |
HCV genotype 1a | 1 (1.1) | 3 (2.5) | 0.476 |
HCV genotype 1b | 87 (98.9) | 119 (97.5) | |
Serum albumin, g/L | 41 (38-43) | 41 (39-43) | 0.376 |
Alanine aminotransferase, U/L | 46 (25-73) | 51 (33-81) | 0.176 |
Alanine aminotransferase ≥ 40 IU/L | 49 (55.7) | 78 (63.9) | 0.228 |
γ-glutamyl-transpeptidase, U/L | 39 (23-76) | 37 (21-63) | 0.199 |
Estimated glomerular filtration rate, mL/min per 1.73 m2 | 80 (68-94) | 81 (71-94) | 0.464 |
Total cholesterol, mg/dL | 175 (153-192) | 164 (146-192) | 0.216 |
Triglycerides, mg/dL | 94 (68-124) | 79 (57-121) | 0.070 |
Aspartate aminotransferase to platelet ratio index | 0.86 (0.51-1.85) | 0.76 (0.50-1.40) | 0.306 |
White blood cell count, × 106/L | 4780 (4038-5890) | 4600 (3890-5645) | 0.447 |
Hemoglobin level, g/L | 137 (129-144) | 135 (126-145) | 0.319 |
Platelet count, × 109/L | 156 (122-195) | 178 (136-209) | 0.040 |
Diabetes | 10 (11.3) | 7 (5.7) | 0.144 |
Stage of fibrosis | |||
F0-2 | 52 (81.2) | 76 (90.5) | 0.105 |
F3-4 | 12 (18.8) | 8 (9.5) | |
Not determined, n | 24 | 38 | |
Previous treatment response | |||
Naïve | 25 (28.4) | ||
Prior relapse | 34 (38.6) | ||
Prior NVR | 27 (30.7) | ||
Prior unknown response | 2 (2.3) | ||
IL28B SNP (rs8099917) | |||
TT | 49 (55.7) | 73 (70.2) | 0.113 |
TG/GG | 39 (44.3) | 31 (29.8) | |
Not determined, n | 0 | 18 |
- Citation: Takayama K, Furusyo N, Ogawa E, Ikezaki H, Shimizu M, Murata M, Hayashi J. Direct-acting antiviral-based triple therapy on alpha-fetoprotein level in chronic hepatitis C patients. World J Gastroenterol 2015; 21(15): 4696-4706
- URL: https://www.wjgnet.com/1007-9327/full/v21/i15/4696.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i15.4696